News &amp; Updates

Women with refractory overactive bladder (OAB) may improve their symptoms by using either intradetrusor onabotulinumtoxinA or combined pharmacotherapy with solifenacin and mirabegron, suggests a study.

02 Oct 2025

Visual distraction eases pain, anxiety during colonoscopy

Patients undergoing colonoscopy may benefit from visual/audiovisual distraction interventions, which have been shown to reduce pain and anxiety and improve satisfaction during the procedure, suggests a recent study.

JAK inhibitor a new hope for new-onset T1D?

The 2-year outcomes from the phase II BANDIT* trial confirm the potential of the Janus kinase (JAK) inhibitor baricitinib for the treatment of new-onset type 1 diabetes (T1D).

02 Oct 2025

Pembrolizumab plus chemo efficacious in advanced PSCC

Treatment with the combination of pembrolizumab plus chemotherapy elicits response in patients with advanced penile squamous cell carcinoma (PSCC) while having a manageable safety profile, according to the phase II HERCULES trial.

Awareness rising, yet breast cancer screening rates continue to lag behind

Many women in Malaysia are still hesitant to go for regular breast cancer screening despite being aware of its importance.

02 Oct 2025

Balancing hope and healing in managing gynaecological tumours in children and adolescents

Gynaecological tumours such as ovarian tumours in children and adolescents present complex diagnostic, emotional, and treatment challenges for young patients, families, and healthcare providers.

02 Oct 2025

Antenatal betamethasone lowers risk of respiratory morbidity in late preterm twin neonates

Antenatal administration of betamethasone in women with twin pregnancies at risk of late preterm delivery appears to reduce the risk of neonatal respiratory morbidity, as shown in a study.

Extended risankizumab treatment for CD may be needed in some patients

01 Oct 2025 by

For some patients with Crohn’s disease (CD) who show no response to induction treatment with risankizumab, extending the treatment course is safe and improves clinical and endoscopic outcomes, as shown in a study.

Brain fog common in patients with GI disorders

Half of the patients with common gastrointestinal (GI) disorders report experiencing brain fog (BF), reveals a study. BF prevalence is higher in patients on probiotics and those with gastroparesis and irritable bowel syndrome (IBS).